Beyond PI3Ks: targeting phosphoinositide kinases in disease.
Nat Rev Drug Discov
; 22(5): 357-386, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-36376561
ABSTRACT
Lipid phosphoinositides are master regulators of almost all aspects of a cell's life and death and are generated by the tightly regulated activity of phosphoinositide kinases. Although extensive efforts have focused on drugging class I phosphoinositide 3-kinases (PI3Ks), recent years have revealed opportunities for targeting almost all phosphoinositide kinases in human diseases, including cancer, immunodeficiencies, viral infection and neurodegenerative disease. This has led to widespread efforts in the clinical development of potent and selective inhibitors of phosphoinositide kinases. This Review summarizes our current understanding of the molecular basis for the involvement of phosphoinositide kinases in disease and assesses the preclinical and clinical development of phosphoinositide kinase inhibitors.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Virus Diseases
/
Neurodegenerative Diseases
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Nat Rev Drug Discov
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2023
Document type:
Article
Affiliation country:
Canadá